+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Enoxaparin"

From
Lab-synthesized Heparin Market - Global Forecast 2025-2030 - Product Thumbnail Image

Lab-synthesized Heparin Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 195 Pages
  • Global
From
Thrombosis Drug Market - Global Forecast 2025-2030 - Product Thumbnail Image

Thrombosis Drug Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 196 Pages
  • Global
From
Heparin Market Report 2025 - Product Thumbnail Image

Heparin Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Anticoagulants Market Report 2025 - Product Thumbnail Image

Anticoagulants Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Low Molecular Weight Heparin Market Report 2025 - Product Thumbnail Image

Low Molecular Weight Heparin Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Myocardial Infarction Market Report 2025 - Product Thumbnail Image

Myocardial Infarction Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Heparin Market Report and Forecast 2025-2034 - Product Thumbnail Image

Heparin Market Report and Forecast 2025-2034

  • Report
  • July 2025
  • 350 Pages
  • Global
From
From
From
  • 17 Results (Page 1 of 1)
Loading Indicator

Enoxaparin is a cardiovascular drug used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a low molecular weight heparin (LMWH) that works by preventing the formation of blood clots. Enoxaparin is administered by subcutaneous injection and is available in both generic and branded forms. It is often used in combination with other anticoagulants such as warfarin. Enoxaparin is also used to reduce the risk of stroke and heart attack in patients with acute coronary syndrome. Enoxaparin is a widely used drug in the cardiovascular market and is available in many countries around the world. It is often prescribed as a first-line treatment for DVT and PE, and is also used in the prevention and treatment of other cardiovascular conditions. Some companies in the Enoxaparin market include Sanofi, Pfizer, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more